Endoscopic treatment of chronic pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline

1. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323(7308): 334–336.

2. Freeman ML, Nelson DB, Sherman S et al. Complications of endoscopic bi­liary sphincterotomy. N Engl J Med 1996; 335(13): 909–918.

3. Choi CW, Kang DH, Kim GH et al. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for ­post-ERCP pancreatitis. Gastrointest ­Endosc 2009; 69(4): e11–e18.

4. Lee KT, Lee DH, Yoo BM. The prophylactic effect of somatostatin on post-thera­peutic endoscopic retrograde cholangio­pancreatography pancreatitis. Pancreas 2008; 37(4): 445–448.

5. Cotton PB, Lehman G, Vennes J et al. Endo­scopic sphincterotomy complica­tions and their management: an attempt at consensus. Gastrointest Endosc 1991; 37(3): 383–393.

6. Bradley EL. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, GA, September 11 through 13, 1992. Arch Surg 1993; 128(5): 586–590.

7. Testoni PA, Caporuscio S, Bagnolo F, Lella F. Twenty-four-hour serum amylase predicting pancreatic reaction after endo­scopic sphincterotomy. Endoscopy 1999; 31(2): 131–136.

8. Bretthauer M, Seip B, Aasen S et al. Carbon dioxide insufflation for more comfortable endoscopic retrograde cholangiopancreatography: a randomized, controlled, double-blind trial. Endoscopy 2007; 39(1): 58–64.

9. Andriulli A, Loperfido S, Napolitano G et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102(8):  1781–1788.

10. Masci E, Mariani A, Curioni S et al. Risk factors for pancreatitis following endo­scopic retrograde cholangiopancreatography: a metaanalysis. Endoscopy 2003; 35(10): 830–834.

11. Freeman ML, DiSario JA, Nelson DB et al. Risk factors for post-ERCP pancrea­titis: a prospective, multicenter study. Gastro­intest Endosc 2001; 54(4): 425–434.

12. Loperfido S, Angelini G, Benedetti G et al. Major early complications from dia­gnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest ­Endosc 1998; 48(1): 1–10.

13. Masci E, Toti G, Mariani A et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96(2): 417–423.

14. Williams EJ, Taylor S, Fairclough P et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. Endoscopy 2007; 39(9): 793–801.

15. Harewood GC, Pochron NL, Gostout CJ. Prospective, randomized, controlled trial of prophylactic pancreatic stent placement for endoscopic snare excision of the duo­denal ampulla. Gastrointest Endosc 2005; 62(3): 367–370.

16. Norton ID, Gostout CJ, Baron TH et al. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc 2002; 56(2): 239–243.

17. Fazel A, Quadri A, Catalano MF, Meyer­son SM, Geenen JE. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastro­intest Endosc 2003; 57(3): 291–294.

18. Smithline A, Silverman W, Rogers D et al. Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc 1993; 39(5): 652–657.

19. Tarnasky PR, Palesch YY, Cunningham JT et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998; 115(6): 1518–1524.

20. Andriulli A, Forlano R, Napolitano G et al. Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography: a systematic analysis of benefits and associated risks. Digestion 2007; 75(2–3): 156–163.

21. Williams EJ, Taylor S, Fairclough P et al. Are we meeting the standards set for endoscopy? Results of a large-scale prospective survey of endoscopic retrograde cholangio-pancreatograph practice. Gut 2007; 56(6): 821–829.

22. Varadarajulu S, Kilgore ML, Wilcox CM et al. Relationship among hospital ERCP volume, length of stay, and technical outcomes. Gastrointest Endosc 2006; 64(3):  338–347.

23. Allison MC, Ramanaden DN, Fouweather MG et al. Provision of ERCP services and training in the United Kingdom. Endo­scopy 2000; 32(9): 693–699.

24. Hilsden RJ, Romagnuolo J, May GR. Patterns of use of endoscopic retrograde cholangiopancreatography in a Canadian province. Can J Gastroenterol 2004; 18(10): 619–624.

25. Colton J, Curran C. Quality indicators, including complications, of ERCP in a community setting: a prospective study. Gastro­intest Endosc 2009; 70(3): 457–467.

26. Rabenstein T, Roggenbuck S, Framke B et al. Complications of endoscopic sphincterotomy: can heparin prevent acute pancreatitis after ERCP? Gastrointest Endosc 2002; 55(4): 476–483.

27. Gottlieb K, Sherman S, Pezzi J, Esber E, Lehman GA. Early recognition of ­post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Am J Gastro­enterol 1996; 91(8): 1553–1557.

28. Testoni PA, Bagnolo F. Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis. Gastrointest Endosc 2001; 53(1): 33–39.

29. Kapetanos D, Kokozidis G, Kinigopoulou P et al. The value of serum amylase and elastase measurements in the prediction of post-ERCP acute pancreatitis. Hepato­gastroenterology 2007; 54(4): 556–560.

30. Thomas PR, Sengupta S. Prediction of pancreatitis following endoscopic retrograde cholangiopancreatography by the 4-h post procedure amylase level. J Gastro­enterol Hepatol 2001; 16(8): 923–926.

31. Ito K, Fujita N, Noda Y et al. Relationship between post-ERCP pancreatitis and the change of serum amylase level after the procedure. World J Gastroenterol 2007; 13(28): 3855–3860.

32. Dai H-F, Wang X-W, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int 2009; 8(1): 11–16.

33. Elmunzer B, Waljee A, Elta G et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57(9): 1262.

34. Zheng M-H, Xia H, Chen Y-P. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis. Gut 2008; 57(11): 1632.

35. Bang UC, Nojgaard C, Andersen PK, Matzen P. Meta-analysis: Nitroglycerin for prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther 2009; 29(10): 1078–1085.

36. Shao LM, Chen QY, Chen MY, Cai JT. Nitro­glycerin in the prevention of post-ERCP pancreatitis: a meta-analysis. Dig Dis Sci 2010; 55(1): 1–7.

37. Raty S, Sand J, Pulkkinen M, Matikainen M, Nordback I. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastro­intest Surg 2001; 5(4): 339–345.

38. Andriulli A, Clemente R, Solmi L et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56(4): 488–495.

39. Andriulli A, Solmi L, Loperfido S et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004; 2(8): 713–718.

40. Arvanitidis D, Anagnostopoulos GK, Gian­nopoulos D et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastro­enterol Hepatol 2004; 19(3): 278–282.

41. Benvenutti S, Zancanella L, Piazzi L et al. Prevention of post-ERCP pancreatitis with somatostatin versus gabexate mesylate: A randomized placebo controlled multicenter study. Dig Liv Dis 2006; 38: S15.

42. Bordas JM, Toledo-Pimentel V, Llach J et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 1998; 47(3): 230–234.

43. Persson B, Slezak P, Efendic S et al. Can somatostatin prevent injection pancreatitis after ERCP? Hepatogastroenterology 1992; 39(3): 259–261.

44. Poon RT, Yeung C, Liu CL et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomised controlled trial. Gut 2003; 52(12):  1768–1773.

45. Poon RT, Yeung C, Lo CM et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999; 49(5): 593–598.

46. Saari A, Kivilaakso E, Schroder T. The influence of somatostatin on pancreatic irritation after pancreatography. An experimental and clinical study. Surg Res Comm 1988; 2: 271–278.

47. Arcidiacono R, Gambitta P, Rossi A et al. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 1994; 26(9): 715–718.

48. Duvnjak M, Supanc V, Simicevic VN et al. Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography. Acta Med Croatica 1999; 53(3): 115–118.

49. Hardt PD, Kress O, Fadgyas T et al. Octreotide in the prevention of pancreatic damage induced by endoscopic sphincterotomy. Eur J Med Res 2000; 5(4): 165–170.

50. Li ZS, Pan X, Zhang WJ et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol 2007; 102(1): 46–51.

51. Manolakopoulos S, Avgerinos A, Vlachogiannakos J et al. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial. Gastro­intest Endosc 2002; 55(4): 470–475.

52. Sternlieb JM, Aronchick CA, Retig JN et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992; 87(11): 1561–1566.

53. Testoni PA, Bagnolo F, Andriulli A et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001; 15(7): 965–972.

54. Thomopoulos KC, Pagoni NA, Vagenas KA et al. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastro­intest Endosc 2006; 64(5): 726–731.

55. Cavallini G, Tittobello A, Frulloni L et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy – Italian Group. N Engl J Med 1996; 335(13): 919–923.

56. Manes G, Ardizzone S, Lombardi G et al. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study. Gastrointest ­Endosc 2007; 65(7): 982–987.

57. Xiong GS, Wu SM, Zhang XW et al. Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Braz J Med Biol Res 2006; 39(1): 85–90.

58. Fujishiro H, Adachi K, Imaoka T et al. Ulinastatin shows preventive effect on ­post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastro­enterol Hepatol 2006; 21: 1065–1069.

59. Tsujino T, Komatsu Y, Isayama H et al. Ulinastatin for pancreatitis after endo­scopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastro­enterol Hepatol 2005; 3(4): 376–383.

60. Ueki T, Otani K, Kawamoto K et al. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. J Gastroenterol 2007; 42: 161–167.

61. Yoo JW, Ryu JK, Lee SH et al. Preventive effects of ulinastatin on post-endo­scopic retrograde cholangiopancreatography pancreatitis in highrisk patients: a prospective, randomized, placebo-controlled trial. Pancreas 2008; 37(4): 366–370.

62. Bai Y, Gao J, Shi X et al. Prophylactic corticosteroids do not prevent post-ERCP pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology 2008; 8(4–5): 504–509.

63. Zheng M, Bai J, Yuan B et al. Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis. BMC Gastro­enterol 2008; 8: 6.

64. Gorelick A, Barnett J, Chey W et al. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 2004; 36(2): 170–173.

65. Matsushita M, Takakuwa H, Shimeno N et al. Epinephrine sprayed on the papilla for prevention of post-ERCP pancreatitis. J Gastroenterol 2009; 44(1): 71–75.

66. Schwartz JJ, Lew RJ, Ahmad NA et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest ­Endosc 2004; 59(2): 179–184.

67. Prat F, Amaris J, Ducot B et al. Nifedipine for prevention of post-ERCP pancrea­titis: a prospective, double-blind randomized study. Gastrointest Endosc 2002; 56(2): 202–208.

68. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993; 54(2): 105–111.

69. Bai Y, Gao J, Zhang W et al. Meta-analysis: allopurinol in the prevention of postendoscopic retrograde cholangiopancreatography pancreatitis. Aliment Pharmacol Ther 2008; 28(5): 557–564.

70. Zheng M, Chen Y, Bai J et al. Meta-analysis of prophylactic allopurinol use in ­post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas 2008; 37(3): 247–253.

71. Andriulli A, Annese V. Risk of post-endo­scopic retrograde cholangiopancreato­graphy pancreatitis and ways to prevent it: old myths, a current need? The case of allopurinol. Clin Gastroenterol Hepatol 2008; 6(4): 374–376.

72. Katsinelos P, Kountouras J, Paroutoglou G et al. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc 2005; 62(1): 105–111.

73. Milewski J, Rydzewska G, Degowska M et al. Nacetylcysteine does not prevent ­post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol 2006; 12(23): 3751–3755.

74. Lavy A, Karban A, Suissa A et al. Natural beta-carotene for the prevention of post-ERCP pancreatitis. Pancreas 2004; 29(2): e45–e50.

75. Barkay O, Niv E, Santo E et al. Low-dose heparin for the prevention of ­post-ERCP pancreatitis: a randomized placebo-controlled trial. Surg Endosc 2008; 22(9): 1971–1976.

76. Rabenstein T, Fischer B, Wiessner V et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004; 59(6): 606–613.

77. Deviere J, Le Moine O, Van Laethem JL et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120(2): 498–505.

78. Dumot JA, Conwell DL, Zuccaro G Jr. et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001; 96(7): 2098–2102.

79. Sherman S, Cheng CL, Costamagna G et al. Efficacy of recombinant human interleukin-10 in prevention of post-endo­scopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas 2009; 38(3): 267–274.

80. Sherman S, Cheng C-L, Costamagna G et al. Efficacy of recombinant human interleukin-10 in prevention of post-endo­scopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas 2009; 38(3): 267–274.

81. Kapetanos D, Kokozidis G, Christodoulou D et al. A randomized controlled trial of pentoxifylline for the prevention of ­post-ERCP pancreatitis. Gastrointest Endosc 2007; 66(3): 513–518.

82. Sherman S, Alazmi WM, Lehman GA et al. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of ­post-ERCP acute pancreatitis. Gastrointest Endosc 2009; 69 (3 Pt 1): 462–472.

83. van Westerloo DJ, Rauws EA, Hommes D et al. Pre-ERCP infusion of semapimod, a mitogen-activated protein kinases inhibitor, lowers post-ERCP hyperamylasemia but not pancreatitis incidence. Gastro­intest Endosc 2008; 68(2): 246–254.

84. Terruzzi V, Radaelli F, Meucci G et al. Is the supine position as safe and effective as the prone position for endoscopic retrograde cholangiopancreatography? A prospective randomized study. Endoscopy 2005; 37(12): 1211–1214.

85. Tringali A, Mutignani M, Milano A et al. No difference between supine and prone position for ERCP in conscious sedated patients: a prospective randomized study. Endo­scopy 2008; 40(2): 93–97.

86. Vandervoort J, Soetikno RM, Tham TCK et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56(5): 652–656.

87. Cheon YK, Cho KB, Watkins JL et al. Frequency and severity of post-ERCP pancrea­titis correlated with extent of pancreatic ductal opacification. Gastrointest ­Endosc 2007; 65(3): 385–393.

88. George S, Kulkarni AA, Stevens G et al. Role of osmolality of contrast media in the development of post-ERCP pancrea­titis: a meta-analysis. Dig Dis Sci 2004; 49(3): 503–508.

89. Keswani R, Hovis R, Edmunowicz S et al. Carbon dioxide (CO2) insufflation during ERCP for the reduction of post-procedure pain: preliminary results of a randomized, double-blind controlled trial. Gastrointest Endosc 2008; 67: AB107.

90. Maple JT, Keswani RN, Hovis RM et al. Carbon dioxide insufflation during ERCP for reduction of postprocedure pain: a randomized, doubleblind, controlled trial. Gastro­intest Endosc 2009; 70(2): 278–283.

91. Cennamo V, Fuccio L, Zagari RM et al. Can a wire-guided cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis?: A meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104(9): 2343–2350.

92. Choudhary A, Puli S, Ibdah J et al. Guidewire use for prevention of post ERCP pancreatitis: a meta-analysis of randomized controlled trials. Gastrointest Endosc 2009; 69: AB305.

93. Madhoun M, Te C, Stoner J et al. Does ­wire-guided cannulation prevent ­post-ERCP pancreatitis? A meta-analysis. Gastro­intest Endosc 2009; 69: AB132.

94. Cheung J, Tsoi KK, Quan W-L et al. Guidewire versus conventional contrast cannulation of the common bile duct for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. Gastro­intest Endosc 2009; 70(6): 1211–1219.

95. Verma D, Kapadia A, Adler DG. Pure versus mixed electrosurgical current for endo­scopic biliary sphincterotomy: a meta-analysis of adverse outcomes. Gastro­intest Endosc 2007; 66(2): 283–290.

96. Herreros de Tejada A, Calleja JL, Díaz G et al. Double-guidewire technique for difficult bile duct cannulation: a multicenter randomized, controlled trial. Gastrointest Endosc 2009; 70(4): 700–709.

97. Maeda S, Hayashi H, Hosokawa O et al. Prospective randomized pilot trial of selective biliary cannulation using pancreatic guide-wire placement. Endoscopy 2003; 35(9): 721–724.

98. Ito K, Fujita N, Noda Y et al. Can pancreatic duct stenting prevent post-ERCP pancreatitis in patients who undergo pancreatic guidewire placement for achieving selective biliary cannulation? A prospective randomized controlled trial. Endoscopy 2008; 40 (Suppl 1): A17.

99. Nguyen-Tang T, Dumonceau JM. Double-guidewire technique for difficult bile duct cannulation: why not insert a prophylactic pancreatic stent? Gastrointest ­Endosc 2010; 72(2): 466.

100. Iqbal S, Sharma P, Shah S. Role of double guide wire cannulation during ERCP. Gastrointest Endosc 2008; 67: AB158.

101. Ito K, Fujita N, Noda Y et al. Pan­creatic guidewire placement for achieving selective biliary cannulation during endo­scopic retrograde cholangio-pancreato­graphy. World J Gastroenterol 2008; 14(36): 5595–5600.

102. Patel S, Torres V, Gross G. The early use of the double-wire technique to facilitate difficult biliary cannulation and its impact on post-ERCP pancreatitis. Gastro­intest Endosc 2009; 69: AB159.

103. Gyökeres T, Duhl J, Varsányi M et al. Double guide wire placement for endoscopic pancreaticobiliary procedures. Endoscopy 2003; 35(1): 95–96.

104. Cennamo V, Fuccio L, Repici A et al. Timing of precut procedure does not influence success rate and complications of ERCP procedure: a prospective randomized comparative study. Gastrointest ­Endosc 2009; 69 (3 Pt 1): 473–479.

105. Wang P, Li Z-S, Liu F et al. Risk factors for ERCP-related complications: a prospec­tive multicenter study. Am J Gastroenterol 2009; 104(1): 31–40.

106. Akaraviputh T, Lohsiriwat V, Swangsri J et al. The learning curve for safety and success of precut sphincterotomy for therapeutic ERCP: a single endoscopist’s experience. Endoscopy 2008; 40(6): 513–516.

107. Fukatsu H, Kawamoto H, Harada R et al. Quantitative assessment of technical proficiency in performing needle--knife precut papillotomy. Surg Endosc 2009; 23(9): 2066–2072.

108. Harewood GC, Baron TH. An assessment of the learning curve for precut biliary sphincterotomy. Am J Gastroenterol 2002; 97(7): 1708–1712.

109. Manes G, Di Giorgio P, Repici A et al. An analysis of the factors associated with the development of complications in patients undergoing precut sphincterotomy: a prospective, controlled, randomized, multicenter study. Am J Gastroenterol 2009; 104(10): 2412–2417.

110. deWeerth A, Seitz U, Zhong Y et al. Primary precutting versus conventional over-the-wire sphincterotomy for bile duct access: a prospective randomized study. Endoscopy 2006; 38(12): 1235–1240.

111. Tang S-J, Haber GB, Kortan P et al. Precut papillotomy versus persistence in difficult biliary cannulation: a prospective randomized trial. Endoscopy 2005; 37(1): 58–65.

112. Yasuda I, Tomita E, Enya M et al. Can endoscopic papillary balloon dilation really preserve sphincter of Oddi function? Gut 2001; 49(5): 686–691.

113. Baron TH, Harewood GC. Endo­scopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: a metaanalysis of randomized, controlled trials. Am J Gastroenterol 2004; 99(8): 1455–1460.

114. Weinberg BM, Shindy W, Lo S. Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stones. Cochrane Database Syst Rev 2006; CD004890.

115. DiSario JA, Freeman ML, Bjorkman DJ et al. Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones. Gastroenterology 2004; 127(5): 1291–1299.

116. Attasaranya S, Cheon Y, Vittal H et al. Large-diameter biliary orifice balloon dilation to aid in endoscopic bile duct stone removal: a multicenter series. Gastrointest Endosc 2008; 67(7): 1046–1052.

117. Ersoz G, Tekesin O, Ozutemiz AO et al. Biliary sphincterotomy plus dilation with a large balloon for bile duct stones that are difficult to extract. Gastrointest Endosc 2003; 57(2): 156–159.

118. Maydeo A, Bhandari S. Balloon sphincteroplasty for removing difficult bile duct stones. Endoscopy 2007; 39(11): 958–961.

119. Minami A, Hirose S, Nomoto T et al. Small sphincterotomy combined with papillary dilation with large balloon permits retrieval of large stones without mechanical lithotripsy. World J Gastroenterol 2007; 13(15): 2179–2182.

120. Misra SP, Dwivedi M. Large-diameter balloon dilation after endoscopic sphincterotomy for removal of difficult bile duct stones. Endoscopy 2008; 40(3): 209–213.

121. Heo JH, Kang DH, Jung HJ et al. Endo­scopic sphincterotomy plus large-balloon dilation versus endoscopic sphincterotomy for removal of bile-duct stones. Gastro­intest Endosc 2007; 66(4): 720–726.

122. Kawamoto M, Geenen J, Omari T et al. Sleeve sphincter of Oddi (SO) manometry: a new method for characterizing the motility of the sphincter of Oddi. J Hepatobiliary Pancreat Surg 2008; 15(4): 391–396.

123. Frenz MB, Wehrmann T. Solid state biliary manometry catheter: impact on dia­gnosis and post-study pancreatitis. Curr Gastroenterol Rep 2007; 9(2): 171–174.

124. Craig AG, Omari T, Lingenfelser T et al. Development of a sleeve sensor for measurement of sphincter of Oddi motility. Endo­scopy 2001; 33(8): 651–657.

125. Sherman S, Troiano FP, Hawes RH, Lehman GA. Sphincter of Oddi manometry: decreased risk of clinical pancreatitis with use of a modified aspirating catheter. Gastro­intest Endosc 1990; 36(5): 462–466.

126. Draganov P, Kowalczyk L, Forsmark C. Prospective trial comparing solid-state catheter and water-perfusion triple-lumen catheter for sphincter of Oddi manometry done at the time of ERCP. Gastrointest ­Endosc 2009; 70(1): 92–95.

127. Wehrmann T, Stergiou N, Schmitt T, Die­trich CF, Seifert H. Reduced risk for pancreatitis after endoscopic microtransducer manometry of the sphincter of Oddi: a randomized comparison with the perfusion manometry technique. Endoscopy 2003; 35(6): 472–477.

128. Sherman S, Hawes RH, Troiano FP, Lehman GA. Pancreatitis following bile duct sphincter of Oddi manometry: utility of the aspirating catheter. Gastrointest Endosc 1992; 38(3): 347–350.

129. Singh P, Das A, Isenberg G et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancrea­titis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60(4): 544–550.

130. Sofuni A, Maguchi H, Itoi T et al. Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent. Clin Gastroenterol Hepatol 2007; 5(11): 1339–1346.

131. Chahal P, Tarnasky P, Petersen B et al. Short 5Fr vs long 3Fr pancreatic stents in patients at high risk for post- endoscopic cholangiopancreatography pancrea­titis. Clin Gastroenterol Hepatol 2009; 7(8): 834–839.

132. Fehmi SMA, Schoenfeld PS, Scheiman JM et al. 5 Fr prophylactic pancreatic stents are easier to place and require fewer guide wires than 3 Fr stents. Gastrointest Endosc 2008; 67: AB328–AB329.

133. Smith MT, Sherman S, Ikenberry SO et al. Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy. Gastrointest Endosc 1996; 44(3): 268–275.

134. Das A, Singh P, Sivak MV et al. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis. Gastrointest Endosc 2007; 65(7): 960–968.

135. Freeman ML, Overby C, Qi D. Pan­creatic stent insertion: consequences of failure and results of a modified technique to maximize success. Gastrointest Endosc 2004; 59(1): 8–14.

136. Brackbill S, Young S, Schoenfeld P, Elta G. A survey of physician practices on prophylactic pancreatic stents. Gastro­intest Endosc 2006; 64(1): 45–52.

137. Dumonceau JM, Rigaux J, Kahaleh M et al. Prophylaxis of post-ERCP pancreatitis: a practice survey. Gastrointest Endosc 2010; 71(6): 934–939.